Drug Manufacturing: Industry Urges FDA “For Cause” Preapproval Inspections
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider moving to "for cause" preapproval inspections (PAIs) as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24